NCT00121277View on ClinicalTrials.gov

Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

August 31, 2009

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

capecitabine

DRUG

vorinostat

Trial Locations (2)

K1H 8L6

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00121277 - Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | Biotech Hunter | Biotech Hunter